Drug Profile
MYO 103
Alternative Names: MYO103; SRP-9005Latest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Nationwide Children's Hospital
- Developer Myonexus Therapeutics; Nationwide Children's Hospital
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Limb girdle muscular dystrophies
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for preclinical development in Limb-girdle-muscular-dystrophies in USA (Parenteral)
- 22 Mar 2022 MYO 103 is still in preclinical trials for Limb girdle muscular dystrophies in USA (Parenteral)
- 14 Jun 2018 Sarepta Therapeutics enters into a manufacturing agreement with Brammer Bio for its micro-dystrophin Duchenne muscular dystrophy and Limb girdle muscular dystrophy gene therapy programs